PRIMARY
REGIMENS : IV
ANTIBIOTICS
Antibiotics Class
|
Dosage range
|
Dosage Adjustment
|
Penicillins
|
||
Ticarcillin-clavulanate
|
3.1g q4h
|
CrCL <50
= 3.1g bd/tds
CrCL <10 = 2g bd |
Piperacillin-tazobactam
|
4.5g q6h
|
CrCL >40 = 4.5g
qid
CrCL <40 = 3.375g
qid
CrCL <20 = 2.25g
qid
|
Cephalosporins
|
||
Ceftazidime
|
2g tds
|
CrCL >50-90 = 2g
bd/tds
CrCL <50 = 2g od/bd
CrCL <10 = 2g od
or eod
|
Cefoperazone
|
2g bd
|
|
Cefepime
|
2g tds
|
CrCL >60 = 2g
bd/tds
CrCL <60 = 2g bd
CrCL <30 = 2g od
CrCL <11 = 1g od
|
Monobactam
|
||
Aztreonam
|
2g tds
|
CrCL > 50-90 = 2g
tds
CrCL <50 = 1-1.5g
tds
CrCL <10 = 500mg
tds
|
Fluoroquinolones
|
||
Ciprofloxacin
|
400mg tds
|
CrCL >50-90 = 400mg
bd
CrCL <50 = 400mg
od
CrCL <10 = 400mg
od
|
Levofloxacin has no advantage
over ciprofloxacin in term of coverage. Levofloxacin primarily indicated for
Respiratory Tract Infection. But 750mg/day can be used in polymicrobial
infection susceptible to streptococci and P. aeruginosa.
Other agents are not
recommended (eg: Moxifloxacin)
|
||
Carbapenems
|
||
Meropenem
|
1g tds
|
CrCL
>50-90 = 1g tds
CrCL <50
= 1g bd
CrCL <25
= 0.5g bd
CrCL <10 = 0.5g od |
Doripenem
|
500mg tds
|
CrCL >50
= No adjustment
CrCL <50
= 250mg tds
CrCL <30 = 250mg bd |
MIC:
Doripenem<
Meropenem < Imipenem
Imipenem less
recommended due to higher risk of resistance developing during treatment
*All agents
associated with resistance emergence thus reserved in cases resistant to all
other agents or polymicrobial infections
|
||
Other antibiotics
|
||
Colistin (Polymyxin
E)
|
3MU(240mg) tds
(NAG), 2.5 – 5mg/kg/day of CBA in 2-4 divided doses (Lexicomp) equivalent to
6.675mg – 13.35mg/kg/day of CMS in 2-4 divided doses
12,500IU CMS=1mg CMS
2.67mg CMS=1mg CBA
|
CrCL >50 = No adjustment
CrCL <50 = 3MU (240mg CMS) bd
CrCL <20
= 3MU (240mg CMS) od (Antibiotics Guidelines)
|
Polymyxin B
|
IV Loading 2.5mg/kg then
12 hours later 1.5mg/kg.Repeat q12h
10,000IU = 1mg
|
No renal adjustment
|
Used in treatment of
MDR P.aeruginosa
|
ORAL ANTIBIOTICS: Only Fluoroquinolones
DRUGS
|
DOSING
|
DOSAGE ADJUSTMENT
|
Ciprofloxacin
|
750mg q12h
|
CrCL >50-90 = 500 – 750mg bd
CrCL <50 = 250 – 500mg bd
CrCL
<10 = 500mg od |
Levofloxacin
|
750mg od
|
CrCL >50-90 = 750mg od
CrCL <50 = 750mg q48h
CrCL
<20 = 750mg once then 500mg q48h |
ALTERNATIVE REGIMENS
DRUGS
|
DOSING
|
DOSAGE ADJUSTMENT
|
Imipenem-cilastatin
|
IV 500mg qid
|
CrCL >50-90 = 500mg qid
CrCL <50 = 250mg bd/tds
CrCL <10 = 125-250mg bd
|
Tobramycin
|
IV Loading dose of 7mg/kg then 5.1mg/kg od
|
CrCL <80 = 4mg/kg od
CrCL <60 = 3.5mg/kg od
CrCL <40 = 2.5mg/kg od
CrCL <30 = 4mg/kg q48h
CrCL <20 = 3mg/kg q48h
CrCL <10 = 2mg/kg q72h AD
|
Gentamicin
|
IV Loading dose 7mg/kg then 5.1mg/kg od
|
CrCL <80 = 4mg/kg od
CrCL <60 = 3.5mg/kg od
CrCL <40 = 2.5mg/kg od
CrCL <30 = 4mg/kg q48h
CrCL <20 = 3mg/kg q48h
CrCL <10 = 2mg/kg q72h AD
|
Amikacin*
|
IV 15mg/kg od
|
CrCL <80 = 12mg/kg od
CrCL <60 = 7.5mg/kg od
CrCL <40 = 4mg/kg od
CrCL <30 = 7.5mg/kg q48h
CrCL <20 = 4mg/kg q48h
CrCL <10 = 3mg/kg q72h AD
|
Aminoglycosides are used only in combination with a beta-lactam
or fluoroquinolones (except for UTI)
Aminoglycosides can be stopped after 3-5 days in patient on
combination therapy who are responding to treatment.
*Maybe active even if Gentamicin and Tobramycin resistant
|
Empiric therapy
- Usage of two agents from different classes
with in vitro activity against P. aeruginosa are recommended for empiric
treatment of serious infections known or suspected to be caused by P.
aeruginosa when there is high risk of antimicrobial resistance or when they
occur in hosts for whom inappropriate antibiotic therapy would likely be associated
with an especially high mortality.
- Classic combination is high dose Piperacillin/Tazobactam
+ Gentamicin/ Tobramycin
- Combination therapy increase the likelihood
that at least one drug is active
Directed therapy
National Antibiotic Guideline 2014- Once results of susceptibility are available, definitive therapy can be tailored accordingly.
- For most infections, definitive
therapy with a single active agent is appropriate, as there is no convincing clinical data that
demonstrate a mortality benefit to combination therapy.
INFECTIONS
|
PREFERRED
|
ALTERNATIVE
|
Pyonephrosis/ Perinephric
Abscess
|
IV Augmentin 1.2g tds + IV Gentamicin 5mg/kg od
OR
IV Cefoperazone 1g bd
|
IV Ciprofloxacin 200-400mg bd
|
Renal Abscess
|
IV Unasyn 1.5g tds followed by 375mg PO bd
Or
IV Cefuroxime 750-1500mg tds followed by 250mg PO bd
PLUS/MINUS
Gentamicin 5mg/kg od (min 2weeks)
|
Ceftriaxone 1-2g od
|
Prostatic Abscess
|
IV Ciprofloxacin 200-400mg bd followed by 500mg PO bd min of 2-4
weeks
|
IV Cefoperazone 1g bd followed by Cefuroxime 500mg PO bd min 2-4
weeks
|
Epididymo-orchitis
|
Ciprofloxacin 500mg PO bd min of 2 weeks
|
|
Testicular Abscess
|
IV Augmentin 1.2g tds
Or
IV Unasyn 1.5g tds
|
IV Cefoperazone 1g bd
|
Urosepsis
|
IV Cefepime 1g bd
Or
IV Imipenem/Cilastatin 500mg tds
|
IV Cefoperazone/Sulbactam 1g
|
Diabetic Foot Infection
|
IV Tazocin 4.5mg tds/qid
|
|
Necrotizing Fasciitis
|
IV Cefoperazone 1g bd + IV Metronidazole 500mg tds
|
IV Cefoperazone/Sulbactam 1g bd + IV Metronidazole 500mg tds
Or
IV Tazocin 4.5g tds
|
Burn Wound Sepsis
|
IV Tazosin 4.5g tds/qid
|
IV Cefepime 1-2g tds
|
Bites
Duration of Tx= 10 days
|
PO Augmentin 625mg tds
|
PO Doxycycline 100mg bd + PO Clindamycin 300mg qid
IF SEVERE
IV Unasyn 1.5-3g tds/qid
OR
IV Tazosin 4.5g tds
|
REFERENCES
1. www.uptodate.com
2. Sanford Guide to Antimicrobial Therapy
3. National Antibiotics Guidelines 2014
4. Guide to Antimicrobial Therapy in the Adult ICU 2012
5. Lexicomp
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.